Jan. 17, 2021, 12:06 a.m. EST

Barotrauma Market 2021 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight by Leading Key Players Forecast till 2023

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jan 17, 2021 (Heraldkeepers) -- Barotrauma Market Research Report: Information by Type (Ear, Sinus, Pulmonary Barotrauma), by Type (Otoscopy, Pulmonary Function Test, Lung Perfusion Scan, Pulse Oximetry), by Treatment (Medications, Surgery, Others), End-User - Global Forecast Till 2023

Market Highlights

Owing to the increasing cases of ear barotrauma, technological advancements, increasing healthcare expenditure, unmet medical needs, patent expiration of blockbuster drugs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement, the barotrauma market has evolved significantly.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/5899

However, huge capital investments with low-profit margins, strict FDA regulations, and poor healthcare system in the low and middle-income countries are likely to hamper the growth of the barotrauma market over the forecast period.

It is estimated that the Barotrauma Market is expected to have a CAGR of 6.5% during the forecast period of 2017-2023.

Key Players

Some of the key players in the global barotrauma market are 3M, Accurate Surgical & Scientific Instruments Corporation, AptarGroup, AstraZeneca plc., Atos Medical, CellScope, Entellus Medical Inc., GlaxoSmithKline plc, HEINE, Inventis, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Olympus Corporation, Pfizer, Inc., Cipla Ltd., Mylan N.V., Preceptis Medical, Rudolf Riester GmbH, Shanghai Yuejin, SinuSys Corporation, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., Sklar Surgical Instruments, Smith & Nephew Plc, Valeant pharmaceuticals International Inc., Hill-Rom, and others.

Segmentation

The global barotrauma market is segmented by type, diagnosis, treatment, and end-user.

On the basis of type, the barotrauma market is classified as ear barotrauma, sinus barotrauma, and pulmonary (lung) barotrauma.

On the basis of diagnosis, the barotrauma market is classified as otoscopy, X-ray, Computed Tomography (CT) scan, pulmonary function test, lung perfusion scan, Magnetic Resonance Imaging (MRI), pulse oximetry, and others.

On the basis of treatment, the barotrauma market is classified as pressure relief, medications, surgery, oxygen treatment, recompression therapy, and others. The medications segment is further classified as decongestant nasal sprays, oral decongestants, oral antihistamines, painkillers, antibiotics, and others. The surgery segment is further classified as Functional Endoscopic Sinus Surgery (FESS), tympanostomy, Single Laparoscopic Incision Transabdominal (SLIT), and others.

On the basis of end-user, the barotrauma market is segmented into hospitals and clinics, trauma centers, pharmaceutical companies, medical device companies, academic and research institutes, and others.

Regional Analysis

The Americas dominates the barotrauma market owing to the increasing prevalence of ear barotrauma and high healthcare expenditure.

Europe holds the second position in the barotrauma market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European barotrauma market. The increasing healthcare expenditure is also boosting the European barotrauma market.

According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.